TEL AVIV, Israel, Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. GLMD ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH"), announced today that it will host a conference call and webcast on Monday, November 5, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the three and nine  months ended September 30, 2018.

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. Galmed recently announced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase IIb meeting with the FDA to discuss the results of the ARREST Study and a Phase III study protocol, with a view to initiating a Phase III clinical study of Aramchol in 2019.

View original content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-third-quarter-2018-financial-results-and-provide-business-update-on-monday-november-5-300739290.html

SOURCE Galmed Pharmaceuticals Ltd.